SEC Company Response from NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509) — May 20, 2021
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: May 20, 2021 · CIK: 0000810509 · Accession: 0001437749-21-012911
AI Filing Summary & Sentiment
File numbers found in text: 333-256093
Letter
VIA EDGAR SUBMISSION Division of Corporation Finance Washington, D.C. 20549 Navidea Biopharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-256093) (as amended, the “Registration Statement”)
Re:
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Monday, May 24, 2021, at 6:00 a.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Faith L. Charles of Thompson Hine LLP, at (212) 908-3905, or Kaoru Suzuki at (513) 352-6569. Please also call Faith L. Charles or Kaoru Suzuki as soon as the Company’s Registration Statement on Form S-1 has been declared effective. Thank you for your attention to this matter.
Sincerely,
NAVIDEA BIOPHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm navb20210520_corresp.htm May 20, 2021 VIA EDGAR SUBMISSION U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Navidea Biopharmaceuticals, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-256093) (as amended, the “Registration Statement”) Dear Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Monday, May 24, 2021, at 6:00 a.m., Eastern Time, or as soon thereafter as is practicable. If you have any questions regarding this request, please contact our outside counsel, Faith L. Charles of Thompson Hine LLP, at (212) 908-3905, or Kaoru Suzuki at (513) 352-6569. Please also call Faith L. Charles or Kaoru Suzuki as soon as the Company’s Registration Statement on Form S-1 has been declared effective. Thank you for your attention to this matter. Sincerely, NAVIDEA BIOPHARMACEUTICALS, INC. By: /s/ Jed A. Latkin Name: Jed A. Latkin Title: Chief Executive Officer, Chief Financial Officer and Chief Operating Officer cc: Faith L. Charles, Thompson Hine LLP Kaoru Suzuki, Thompson Hine LLP